294 related articles for article (PubMed ID: 20703245)
1. Par2 inactivation inhibits early production of TSLP, but not cutaneous inflammation, in Netherton syndrome adult mouse model.
Briot A; Lacroix M; Robin A; Steinhoff M; Deraison C; Hovnanian A
J Invest Dermatol; 2010 Dec; 130(12):2736-42. PubMed ID: 20703245
[TBL] [Abstract][Full Text] [Related]
2. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome.
Briot A; Deraison C; Lacroix M; Bonnart C; Robin A; Besson C; Dubus P; Hovnanian A
J Exp Med; 2009 May; 206(5):1135-47. PubMed ID: 19414552
[TBL] [Abstract][Full Text] [Related]
3. Netherton syndrome: skin inflammation and allergy by loss of protease inhibition.
Hovnanian A
Cell Tissue Res; 2013 Feb; 351(2):289-300. PubMed ID: 23344365
[TBL] [Abstract][Full Text] [Related]
4. SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7.
Wang S; Olt S; Schoefmann N; Stuetz A; Winiski A; Wolff-Winiski B
Exp Dermatol; 2014 Jul; 23(7):524-6. PubMed ID: 24848304
[TBL] [Abstract][Full Text] [Related]
5. The 420K LEKTI variant alters LEKTI proteolytic activation and results in protease deregulation: implications for atopic dermatitis.
Fortugno P; Furio L; Teson M; Berretti M; El Hachem M; Zambruno G; Hovnanian A; D'Alessio M
Hum Mol Genet; 2012 Oct; 21(19):4187-200. PubMed ID: 22730493
[TBL] [Abstract][Full Text] [Related]
6. A proinflammatory role of KLK6 protease in Netherton syndrome.
Zingkou E; Pampalakis G; Charla E; Nauroy P; Kiritsi D; Sotiropoulou G
J Dermatol Sci; 2019 Jul; 95(1):28-35. PubMed ID: 31255470
[TBL] [Abstract][Full Text] [Related]
7. KLK5 Inactivation Reverses Cutaneous Hallmarks of Netherton Syndrome.
Furio L; Pampalakis G; Michael IP; Nagy A; Sotiropoulou G; Hovnanian A
PLoS Genet; 2015 Sep; 11(9):e1005389. PubMed ID: 26390218
[TBL] [Abstract][Full Text] [Related]
8. Counterregulation between thymic stromal lymphopoietin- and IL-23-driven immune axes shapes skin inflammation in mice with epidermal barrier defects.
Li J; Leyva-Castillo JM; Hener P; Eisenmann A; Zaafouri S; Jonca N; Serre G; Birling MC; Li M
J Allergy Clin Immunol; 2016 Jul; 138(1):150-161.e13. PubMed ID: 26993035
[TBL] [Abstract][Full Text] [Related]
9. rAAV2-mediated restoration of LEKTI in LEKTI-deficient cells from Netherton patients.
Roedl D; Oji V; Buters JT; Behrendt H; Braun-Falco M
J Dermatol Sci; 2011 Mar; 61(3):194-8. PubMed ID: 21251800
[TBL] [Abstract][Full Text] [Related]
10. Proteolytic activation cascade of the Netherton syndrome-defective protein, LEKTI, in the epidermis: implications for skin homeostasis.
Fortugno P; Bresciani A; Paolini C; Pazzagli C; El Hachem M; D'Alessio M; Zambruno G
J Invest Dermatol; 2011 Nov; 131(11):2223-32. PubMed ID: 21697885
[TBL] [Abstract][Full Text] [Related]
11. Netherton syndrome: defective kallikrein inhibition in the skin leads to skin inflammation and allergy.
Furio L; Hovnanian A
Biol Chem; 2014 Sep; 395(9):945-58. PubMed ID: 25153381
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of interleukin-33 in the epidermis of two Japanese patients with Netherton syndrome.
Konishi T; Tsuda T; Sakaguchi Y; Imai Y; Ito T; Hirota S; Yamanishi K
J Dermatol; 2014 Mar; 41(3):258-61. PubMed ID: 24506793
[TBL] [Abstract][Full Text] [Related]
13. Establishment of a mouse model of Netherton syndrome based on CRISPR/Cas9 technology.
Guo JZ; Su J; Dai H; Wang XY; Wu WB; Chen T; Zhang J; Wang WH
Eur J Dermatol; 2022 Jul; 32(4):459-463. PubMed ID: 36301754
[TBL] [Abstract][Full Text] [Related]
14. Correlation between SPINK5 gene mutations and clinical manifestations in Netherton syndrome patients.
Komatsu N; Saijoh K; Jayakumar A; Clayman GL; Tohyama M; Suga Y; Mizuno Y; Tsukamoto K; Taniuchi K; Takehara K; Diamandis EP
J Invest Dermatol; 2008 May; 128(5):1148-59. PubMed ID: 17989726
[TBL] [Abstract][Full Text] [Related]
15. A heterozygous null mutation combined with the G1258A polymorphism of SPINK5 causes impaired LEKTI function and abnormal expression of skin barrier proteins.
Di WL; Hennekam RC; Callard RE; Harper JI
Br J Dermatol; 2009 Aug; 161(2):404-12. PubMed ID: 19438860
[TBL] [Abstract][Full Text] [Related]
16. Cathelicidin represents a new target for manipulation of skin inflammation in Netherton syndrome.
Zingkou E; Pampalakis G; Sotiropoulou G
Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165831. PubMed ID: 32442469
[TBL] [Abstract][Full Text] [Related]
17. Corneodesmosomal cadherins are preferential targets of stratum corneum trypsin- and chymotrypsin-like hyperactivity in Netherton syndrome.
Descargues P; Deraison C; Prost C; Fraitag S; Mazereeuw-Hautier J; D'Alessio M; Ishida-Yamamoto A; Bodemer C; Zambruno G; Hovnanian A
J Invest Dermatol; 2006 Jul; 126(7):1622-32. PubMed ID: 16628198
[TBL] [Abstract][Full Text] [Related]
18.
Park NJ; Jo BG; Bong SK; Park SA; Lee S; Kim YK; Yang MH; Kim SN
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955819
[TBL] [Abstract][Full Text] [Related]
19. When activity requires breaking up: LEKTI proteolytic activation cascade for specific proteinase inhibition.
Furio L; Hovnanian A
J Invest Dermatol; 2011 Nov; 131(11):2169-73. PubMed ID: 21997416
[TBL] [Abstract][Full Text] [Related]
20. Genetic activation of Nrf2 reduces cutaneous symptoms in a murine model of Netherton syndrome.
Muzumdar S; Koch M; Hiebert H; Bapst A; Gravina A; Bloch W; Beer HD; Werner S; Schäfer M
Dis Model Mech; 2020 Jun; 13(5):. PubMed ID: 32457102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
